CO6700872A2 - Derivados de 1,4-oxazepano - Google Patents

Derivados de 1,4-oxazepano

Info

Publication number
CO6700872A2
CO6700872A2 CO13114306A CO13114306A CO6700872A2 CO 6700872 A2 CO6700872 A2 CO 6700872A2 CO 13114306 A CO13114306 A CO 13114306A CO 13114306 A CO13114306 A CO 13114306A CO 6700872 A2 CO6700872 A2 CO 6700872A2
Authority
CO
Colombia
Prior art keywords
ring
oxazepane
derivatives
optionally substituted
membered aromatic
Prior art date
Application number
CO13114306A
Other languages
English (en)
Inventor
Yuji Ishichi
Masami Yamada
Taku Kamel
Ikuo Fujimori
Yoshihisa Nakada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6700872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6700872A2 publication Critical patent/CO6700872A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto que tiene una actividad inhibidora de la recaptación de monoamina, que está representado por la fórmula (I)en donde el anillo A es un anillo aromático de 6 miembros opcionalmente sustituido, el anillo B esSustituyentes en el anillo A se unen opcionalmente para formar, junto con el anillo A, un anillo fusionado aromático de 9 ó 10 miembros opcionalmente sustituido y los demás símbolos son como se definen en la descripción o una de sus sales.
CO13114306A 2010-10-07 2013-05-07 Derivados de 1,4-oxazepano CO6700872A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010227864 2010-10-07
JP2011175336 2011-08-10

Publications (1)

Publication Number Publication Date
CO6700872A2 true CO6700872A2 (es) 2013-06-28

Family

ID=44906302

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13114306A CO6700872A2 (es) 2010-10-07 2013-05-07 Derivados de 1,4-oxazepano

Country Status (25)

Country Link
US (2) US8722662B2 (es)
EP (1) EP2625170A1 (es)
JP (1) JP5873487B2 (es)
KR (1) KR20130116073A (es)
CN (1) CN103261176B (es)
AR (1) AR083313A1 (es)
AU (1) AU2011313150A1 (es)
BR (1) BR112013008420A2 (es)
CA (1) CA2813911A1 (es)
CL (1) CL2013000927A1 (es)
CO (1) CO6700872A2 (es)
CR (1) CR20130158A (es)
DO (1) DOP2013000074A (es)
EA (1) EA201390491A1 (es)
EC (1) ECSP13012593A (es)
GE (1) GEP20156295B (es)
IL (1) IL225189A0 (es)
MX (1) MX2013003749A (es)
NZ (1) NZ608499A (es)
PE (1) PE20140239A1 (es)
SG (1) SG188346A1 (es)
TW (1) TW201242956A (es)
UY (1) UY33650A (es)
WO (1) WO2012046882A1 (es)
ZA (1) ZA201302112B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859604C (en) * 2011-12-21 2019-12-17 Ono Pharmaceutical Co., Ltd. Compounds
JP6410819B2 (ja) * 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用
CN105693652B (zh) * 2014-11-27 2019-01-08 常州合全药业有限公司 一种4-叔丁基-5-乙基-6-氧亚基-1,4-噁吖庚环-4,5-二甲酸基酯的合成方法
MY194106A (en) 2014-12-10 2022-11-13 Ono Pharmaceutical Co Dihydroindolizinone derivative
CN107848966A (zh) 2015-05-08 2018-03-27 弗特鲁斯控股有限责任公司 将甲酰胺转化为硫代甲酰胺的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3018222A (en) 1956-08-28 1962-01-23 Ravensberg G M B H Central stimulant and appetite depressant composition
US4010166A (en) * 1974-11-25 1977-03-01 Ciba-Geigy Corporation 1,4-Oxazepines
DE3242923A1 (de) * 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen 7-phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre herstellung und verwendung
ES2175083T3 (es) 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
PT885220E (pt) 1996-02-22 2001-11-30 Neurosearch As Derivados de tropano a sua preparacao e utilizacao
DE69733655T2 (de) 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
WO2001079187A2 (en) 2000-04-18 2001-10-25 Cytovia, Inc. Substituted 1,4-thiazepine and analogs and their use as activators of caspases
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
GB0229743D0 (en) * 2002-12-20 2003-01-29 Arakis Ltd Novel benzoxazocines
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
EP2388259A1 (en) 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CN101443014A (zh) * 2006-03-10 2009-05-27 阿斯利康(瑞典)有限公司 化合物
CN101437814A (zh) 2006-05-31 2009-05-20 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的苯并氮杂衍生物
EP2074117A2 (en) 2006-11-24 2009-07-01 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
GB0721178D0 (en) 2007-10-29 2007-12-05 Glaxo Group Ltd Chemical compounds
WO2009119528A1 (ja) 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
WO2010016554A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 環状アミン化合物

Also Published As

Publication number Publication date
IL225189A0 (en) 2013-06-27
ECSP13012593A (es) 2013-07-31
PE20140239A1 (es) 2014-03-07
MX2013003749A (es) 2013-05-09
WO2012046882A1 (en) 2012-04-12
EA201390491A1 (ru) 2013-11-29
US20130267494A1 (en) 2013-10-10
ZA201302112B (en) 2013-12-23
GEP20156295B (en) 2015-06-10
CN103261176A (zh) 2013-08-21
AU2011313150A1 (en) 2013-04-18
DOP2013000074A (es) 2014-07-31
EP2625170A1 (en) 2013-08-14
SG188346A1 (en) 2013-04-30
NZ608499A (en) 2015-03-27
US8722662B2 (en) 2014-05-13
CR20130158A (es) 2013-05-03
JP2013538786A (ja) 2013-10-17
UY33650A (es) 2012-04-30
CA2813911A1 (en) 2012-04-12
CN103261176B (zh) 2015-06-03
JP5873487B2 (ja) 2016-03-01
KR20130116073A (ko) 2013-10-22
AR083313A1 (es) 2013-02-13
TW201242956A (en) 2012-11-01
US20120088748A1 (en) 2012-04-12
BR112013008420A2 (pt) 2016-06-28
CL2013000927A1 (es) 2013-09-13

Similar Documents

Publication Publication Date Title
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2017001533A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
CU20200004A7 (es) Compuestos para tratar afecciones asociadas con la actividad nlrp
CO2017013709A2 (es) Lactamas bicíclicas.
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CR20140547A (es) Compuestos que contienen pirazol sustituido y su uso como plaguicidas
GT201400195A (es) Compuestos de heterociclilo como inhibidores de mek
CR20150250A (es) Nuevos derivados de piridina
CO2017000332A2 (es) Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt)
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
CR20150440A (es) Nuevos derivados de piridina
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
DOP2014000098A (es) 2-tiopirimidinonas
ECSP12011603A (es) Derivados de pirazinooxazepina
BR112019014963A8 (pt) Compostos-bis para dispositivos opticamente ativos
CL2015002697A1 (es) Buje de abertura ascendente y montaje de cabezal de barril central que comprende el mismo.
UY4153Q (es) Batería
CO6700872A2 (es) Derivados de 1,4-oxazepano